DelveInsight’s, “Follicular Lymphoma Pipeline Insight, 2025” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Follicular Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent advances in Follicular Lymphoma Treatment Drugs @ Follicular Lymphoma Pipeline Outlook Report
Key Takeaways from the Follicular Lymphoma Pipeline Report
Find out more about Follicular Lymphoma Therapeutics Assessment @ Follicular Lymphoma Preclinical and Discovery Stage Products
Follicular Lymphoma Emerging Drugs
MIL62 is a third-generation anti-CD20 antibody with a unique competitive position. MIL62 is the first domestically developed third-generation anti-CD20 antibody entering Phase III registration trial in China. MIL62 is self-developed by leveraging our ADCC-enhanced antibody platform. In in vitro and in vivo studies, MIL62 demonstrates stronger ADCC and anti-tumor activities than rituximab (first-generation anti-CD20 antibodies) and obinutuzumab (other third-generation anti-CD20 antibody). The company is implementing critical clinical development strategies to first pursue marketing approval from the NMPA for the treatment of relapsed and/or refractory FL patients and DLBCL patients. At the same time, MIL62 is being developed for previously untreated FL and DLBCL patients (a significantly larger patient population) by demonstrating clinical superiority over rituximab. Currently the drug is in Phase III stage of its development for the treatment of follicular lymphoma.
AZD0486, also known as TNB-486, is an innovative bispecific antibody targeting CD19 and CD3, designed to enhance T-cell-mediated destruction of malignant B cells, particularly in patients with relapsed or refractory follicular lymphoma (FL). AZD0486 functions by engaging T-cells to attack B-cell malignancies, thereby circumventing some limitations associated with traditional therapies. Its design incorporates a low-affinity anti-CD3 moiety, which helps mitigate severe cytokine release syndrome (CRS), a common side effect of T-cell engagers. This unique feature allows for a more controlled immune response, potentially leading to better safety profiles. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Follicular Lymphoma.
Abexinostat (Abx) is a novel, potent, orally administered pan-histone deacetylase inhibitor (HDACi) developed by Xynomic Pharmaceuticals. It is designed to maintain effective anti-tumor concentrations through twice-daily (BID) dosing. Abexinostat targets multiple HDAC enzymes, which are involved in the deacetylation of histones, leading to chromatin remodeling and regulation of gene expression. By inhibiting HDACs, Abexinostat causes the accumulation of acetylated histones, promoting apoptosis, cell cycle arrest, and inhibition of angiogenesis in cancer cells. Additionally, Abexinostat acts as a Rad51 recombinase inhibitor, interfering with DNA repair mechanisms, which enhances its anti-cancer activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Follicular Lymphoma.
ABBV-319 is a CD19-targeting antibody-drug conjugate engineered to reduce glucocorticoid-associated toxicities while possessing 3 distinct mechanisms of action (MOA) to increase therapeutic efficacy: (1) antibody-mediated delivery of a glucocorticoid receptor modulator (GRM) payload to activate apoptosis, (2) inhibition of CD19 signaling, and (3) enhanced fragment crystallizable (Fc)–mediated effector function via afucosylation of the antibody backbone. Currently, the drug is in the Phase I stage of development to treat Follicular Lymphoma.
NX-2127 is an oral small molecule degrader of BTK and cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos). Cereblon immunomodulatory drugs that induce degradation IKZF1 and IKZF3 such as lenalidomide and pomalidomide are FDA approved for a variety of hematologic malignancies including multiple myeloma, follicular lymphoma, and mantle cell lymphoma. We hypothesize that the combination of BTK degradation and cereblon immunomodulatory activity will have enhanced therapeutic benefit in patients suffering from a variety of B-cell malignancies. Initial clinical data support the activity of NX-2127 in patients whose tumors harbor either wild-type BTK or BTK with mutations conferring clinical resistance to FDA approved agents. Initial clinical data also confirm potent BTK degradation with once daily oral dosing. Currently, the drug is in the Phase I stage of its development for the treatment of Follicular Lymphoma.
The Follicular Lymphoma pipeline report provides insights into
Explore the dynamic world of drug development with our latest Follicular Lymphoma Pipeline Insights report! Don’t miss this opportunity to stay informed—download now! @ Follicular Lymphoma Treatment Drugs
Follicular Lymphoma Companies
Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene and others.
Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Follicular Lymphoma Products have been categorized under various Molecule types such as
Learn more about the emerging Follicular Lymphoma Pipeline Therapies @ Follicular Lymphoma Clinical Trials Assessment
Scope of the Follicular Lymphoma Pipeline Report
Which Follicular Lymphoma Companies are leading the way in drug discovery? Download now to stay at the forefront of pharmaceutical innovation!” @ Follicular Lymphoma Emerging Drugs and Companies
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/follicular-lymphoma-pipeline-insight
